Vistagen Therapeutics Inc.

Last updated September 27, 2026

Organization details

Legal name
Vistagen Therapeutics Inc.
Former names
Excaliber Enterprises, Ltd.
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Nevada
Headquarters city
South SAN Francisco
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
March
Ticker symbol
VTGN
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001411685
EIN
20-5093315

Board of directors

Chief executives

Shawn Singh · CHIEF EXECUTIVE OFFICER
Dates unknown

Director election results

Annual meeting of August 26, 2024. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

3 of this board's directors also sit on 3 other boards. 3 are in the same sector.

Network of Vistagen Therapeutics Inc.'s board connections AN2 Therapeutics Inc. AN2 Therapeutics Inc. Alterity Therapeutics Limited Alterity Therapeutics... Xeris Biopharma Holdings Inc. Xeris Biopharma Holdin... Ann Michelle Cunningham Ann Michelle Cunning... Margaret M. FitzPatrick Margaret M. FitzPatr... Paul R. Edick Paul R. Edick Vistagen Therapeutics Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Jun 30, 2026 Adler Reid G. Officer (Chief Legal Officer) Grant or award +36,818 $0.19 $6,995
Jun 30, 2026 Shawn Singh Director, Officer (President and CEO) Grant or award +36,818 $0.19 $6,995
Jun 30, 2026 Tressler Nick B. Officer (Chief Financial Officer) Grant or award +11,712 $0.19 $2,225
Dec 31, 2025 Prince Joshua S. Officer (Chief Operating Officer) Grant or award +4,386 $0.56 $2,456
Jun 30, 2025 Prince Joshua S. Officer (Chief Operating Officer) Grant or award +4,882 $1.70 $8,299
Jun 30, 2025 Adler Reid G. Officer (Chief Legal Officer) Grant or award +7,541 $1.70 $12,820
Jun 30, 2025 Anderson Cynthia Lynn Officer (CHIEF FINANCIAL OFFICER) Grant or award +6,617 $1.70 $11,249
Jun 30, 2025 Shawn Singh Director, Officer (President and CEO) Grant or award +7,541 $1.70 $12,820
Dec 31, 2024 Prince Joshua S. Officer (Chief Operating Officer) Grant or award +3,310 $2.51 $8,308
Dec 31, 2024 Anderson Cynthia Lynn Officer (CHIEF FINANCIAL OFFICER) Grant or award +2,592 $2.51 $6,506
Jun 28, 2024 Prince Joshua S. Officer (Chief Operating Officer) Grant or award +2,671 $2.96 $7,906
Jun 28, 2024 Anderson Cynthia Lynn Officer (CHIEF FINANCIAL OFFICER) Grant or award +3,592 $2.96 $10,632
Jun 28, 2024 Adler Reid G. Officer (CHF CORP DEVEL OFF, GEN COUNS) Grant or award +4,854 $2.96 $14,368
Jun 28, 2024 Shawn Singh Director, Officer (CHIEF EXECUTIVE OFFICER) Grant or award +4,854 $2.96 $14,368
Dec 29, 2023 Adler Reid G. Officer (CHF CORP DEVEL OFF, GEN COUNS) Grant or award +167 $1.72 $287

Organizations in the same sector, closest in location and size first.

Questions about Vistagen Therapeutics Inc.

Who is the CEO of Vistagen Therapeutics Inc.?

Shawn Singh is Vistagen Therapeutics Inc.'s CHIEF EXECUTIVE OFFICER.

How many directors are on Vistagen Therapeutics Inc.'s board?

Vistagen Therapeutics Inc.'s board has 9 directors: Ann Michelle Cunningham, Douglas J. Williamson, Jerry B. Gin, Joanne Curley, Jon S. Saxe, Margaret M. FitzPatrick, Mary L. Rotunno, Paul R. Edick and Shawn Singh.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="vistagen-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.